Insulin-Like Growth Factor I and Impaired Glucose ToleranceDunger D.B. · Yuen K. · Ong K.
University Department of Paediatrics, University of Cambridge, Cambridge, UK
The effects of circulating insulin-like growth factor I (IGF-I) on glucose metabolism are well recognized. IGF-I is also important in maintaining β-cell mass and regulating endogenous growth hormone (GH) levels. Low IGF-I levels could explain links between small birth size and the risk of developing type 2 diabetes mellitus in short, obese adults. In a recent prospective study, childhood insulin secretion was related to IGF-I levels and statural growth, whereas insulin sensitivity was related to early post-natal weight gain. Common genetic polymorphisms in the IGF1 gene have been linked to small birth size, post-natal growth and future diabetes risk, but these results have been inconsistent. Recent adult studies have demonstrated that lower baseline IGF-I levels predict the subsequent development of impaired glucose tolerance (IGT), type 2 diabetes and cardiovascular disease. Administration of low-dose GH therapy, at a dose that minimizes the lipolytic effects of GH and has the ability to increase IGF-I levels, enhances insulin sensitivity in young healthy adults and in GH-deficient adults and increases insulin secretion in individuals with IGT. Whether the administration of low-dose GH, recombinant IGF-I or combined IGF-I/IGF-binding protein 3 therapy prevents future development of IGT or type 2 diabetes in high-risk normoglycaemic and GH-deficient individuals merits further long-term studies.
© 2004 S. Karger AG, Basel
Number of Print Pages : 7
Number of Figures : 2, Number of Tables : 1, Number of References : 57
Hormone Research (From Development Endocrinology to Clinical Research)
Vol. 62, No. Suppl. 1, Year 2004 (Cover Date: Released February 2005)
Journal Editor: P. Czernichow, Paris
ISSN: 0301–0163 (print), 1423–0046 (Online)
For additional information: http://www.karger.com/hre